Impact Report and Annual Report plus Financial Statements 2010 – 2011
With our continued funding of pioneering research, we saw some very encouraging progress. ‘Exon skipping’ technology ismoving closer to clinical trials, bringingreal hope to families affected byDuchenne muscular dystrophy, and anew technique was developed that canallow families affected by mitochondrialmyopathy to have unaffected children.Our campaigns team made greatstrides ahead for individuals andfamilies, in securing more NHS-fundedneuromuscular care advisors in post inthe UK than ever before, and in seeing thelaunch of the first national development strategy from government, callingfor an England-wide neuromuscularservice plan. Progress was achievedin the devolved countries too.
Read more in the Impact Report 2010 – 2011